DATATRAK Announces Settlement of Patent Litigation

CLEVELAND, OH -- (Marketwired) -- 01/06/16 -- DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today announced that it has entered into a settlement agreement with Medidata Solutions, Inc. to resolve all existing patent litigation between the parties.

Under the terms of the settlement agreement, the parties agreed to dismiss the claims against each other in the lawsuits pending in the U.S. District Court for the Northern District of Ohio and the U.S. District Court for the District of New Jersey. Neither party made any payment as part of the settlement. DATATRAK and Medidata also agreed to mutual covenants not to sue with respect to the patents-in-suit and related patents.

About DATATRAK

DATATRAK International, the leader in developing cloud-based, unified dClinical™ platform, is a worldwide technology and consulting company serving the clinical trials industry. The company delivers a portfolio of software solutions that safely accelerate clinical research, from Concept to Cure®.

Join DATATRAK Thought Leaders:

• Twitter
• LinkedIn
• SlideShare
• The DATATRAK Blog

Tweet: #DATATRAK announces patent litigation settlement http://ow.ly/WGuRB

About  DATATRAK
DATATRAK International is a worldwide technology and services company delivering Unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I -- Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Chicago, IL; Cary Research Triangle Park (RTP), North Carolina; Bryan, Texas; and Cleveland, Ohio. For more information, visit http://www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

   Dorothy RadkeDirector MarketingDATATRAK International, Inc.+1-440-443-0082

Source: DATATRAK International , Inc.

You May Also Be Interested In

• Terra Innovatum Global Reports Second Quarter 2026 Financial Results and Announces Webinar to Discuss Operational Progress
• Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
• In HelloNation, Criminal Defense Attorney Frank Walker Explains the Difference Between Misdemeanor and Felony Charges